Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis
Open accessAbstract
Lipoprotein glomerulopathy is an inherited renal disease characterized by unique lipoprotein thrombi in the glomerulus and is associated with the APOE mutation. Hu and colleagues investigated the genetic and clinical features of a large group of patients with lipoprotein glomerulopathy who carried APOE Kyoto, a major APOE variant. Their findings suggest its descent through a founder effect. Fibrate therapy in this group showed favorable results in the patient and renal survival rates.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
APOE Kyoto has been distributed worldwide, not only among Asians in China and Japan, but also among Caucasians in Europe and the USA.
“Furthermore, APOE Kyoto has been distributed worldwide, not only among Asians in China and Japan, but also among Caucasians in Europe and the USA [5, 16, 26].”
From Identification of a founder haplotype of <i>APOE Kyoto</i> variant in lipoprotein glomerulopathy (2025) · cites this paper as [16]
APOE Kyoto is the leading mutation in about 200 patients and is the most common APOE variant worldwide.
“with APOE Kyoto (Arg43Cys) the leading mutation in about 200 patients.”
From Identification of a founder haplotype of <i>APOE Kyoto</i> variant in lipoprotein glomerulopathy (2025) · cites this paper as [16]
Clinical manifestations of LPG patients include mild nephrotic problem initially but later progress to nephrotic syndrome with elevated levels of serum apoE, hyperlipidemia, hypertension and microscopic hematuria.
“Clinical manifestations of LPG patients include mild nephrotic problem initially but later progress to nephrotic syndrome with elevated levels of serum apolipoprotein E (apoE), hyperlipidemia, hypertension and microscopic hematuria (Hu et al., 2014; Saito & Matsunaga, 2014).”
From Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by <i>APOE</i> mutations (2020) · cites this paper as Saito & Matsunaga, 2014
Hu et al. compared patient and kidney survival over 3 years between fenofibrate-treated and control groups, confirming the value of fenofibrate in LPG treatment.
“Hu et al. compared patient and kidney survival over 3 years between fenofibrate-treated and control groups, confirming the value of fenofibrate in LPG treatment71).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [71]
APOE Sendai (Arg145Pro) was observed mainly in central and northern Japan, especially in Yamagata and Miyagi, but not in China.
“APOE Sendai (Arg145Pro) was observed mainly in central and northern Japan, especially in Yamagata and Miyagi, but not in China71, 93).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [71]
Cites
Lipoprotein Glomerulopathy: Glomerular Lipoprotein Thrombi in a Patient With Hyperlipoproteinemia
Saito, T., Sato, H., Kudo, K.-I., Oikawa, S.-I., Shibata, T., Hara, Y., Yoshinaga, K., & Sakaguchi, H. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80134-9 · Cited by 148 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Apolipoprotein E–related glomerular disorders
Saito, T., Matsunaga, A., Fukunaga, M., Nagahama, K., Hara, S., & Muso, E. (2020) · Kidney International · doi:10.1016/j.kint.2019.10.031 · Cited by 77 · see citing works
Self-citationClinical and genetic analysis of lipoprotein glomerulopathy patients caused by <i>APOE</i> mutations
Yang, M., Weng, Q., Pan, X., Hussain, H. M. J., Yu, S., Xu, J., Yu, X., Liu, Y., Jin, Y., Zhang, C., et al. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1281 · Cited by 15 · see citing works
Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14 · see citing works
Self-citationLipoprotein Glomerulopathy, First Case Report from Canada
Ting, J. A., McRae, S. A., Schwartz, D., Barbour, S. J., & Riazy, M. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s364890 · Cited by 7 · see citing works
Li, Y., Chen, J., Zou, Y., Wang, W., & Li, G. (2022) · Medicine · doi:10.1097/md.0000000000028718 · Cited by 5 · see citing works
Identification of a founder haplotype of <i>APOE Kyoto</i> variant in lipoprotein glomerulopathy
Wu, H., He, Z., Yang, J., Zhou, Y., Yang, Z., Hu, Z., & Yang, Y. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf234
- Authors
- Saito, T., & Matsunaga, A.
- Affiliations
- Fukuoka University (JP)
- Corresponding author
- Saito, Takao
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2014
- Volume
- 85
- Issue
- 2
- Pages
- 243-245
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1977089358
- Cited by
- 18
- References
- 1
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1 · 2022: 3 · 2020: 1 · 2019: 3 · 2018: 3 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- lipoprotein glomerulopathy, founder effect, fibrate therapy, hereditary kidney disease, renal survival
- MeSH terms
- Hypolipidemic Agents, Female, Humans, Kidney, Kidney Diseases, Male, Mutation, Fenofibrate, Apolipoprotein E2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
